GSK is to further advance its commitment towards transparency, openness and collaboration, as these attributes are essential to finding new drugs to treat global diseases, according to CEO Sir ...

The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient combination that will compete with Gilead's nearly-approved three-drug regimen.

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, has announced that the Committee for Medicinal ...

GSK plc’s GSK HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive ...